INTRODUCTION
Gastro-oesophageal reflux disease (GERD) is a chronic disorder and a common reason for visits to primary care physicians, gastroenterologists and, more recently, otolaryngologists. Population-based studies estimate that GERD symptoms occur weekly in 8-20% of the population.
1, 2 Among those individuals reporting heartburn at least weekly, 79% report night-time heartburn. 3 Approximately 60% of individuals with night-time symptoms experience interference with sleep, which may affect daytime activities in as many as 40% of these patients. 3 Symptoms of GERD are not limited to the oesophageal complaints characteristically associated with reflux. Atypical chest pain and otolaryngeal and pulmonary problems are common in GERD patients. Unfortunately, these symptoms are often treated without recognition that GERD is potentially contributing to the underlying problem. Night-time symptoms have also been associated with increased prevalence and severity of GERD complications. [4] [5] [6] [7] [8] Despite its prevalence and potentially serious consequences, there are few epidemiological reports, sleep studies or clinical efficacy trials specifically addressing the diagnosis and management of night-time GERD.
DIAGNOSIS

Recognizing oesophageal symptoms
Oesophageal symptoms that are highly specific for reflux include heartburn, regurgitation or both, often occurring after meals (especially large or fatty meals) ( Table 1) . Typically, symptoms are aggravated by recumbency or bending and are relieved by antacids. Although symptom severity does not necessarily correlate with the extent of damage to the mucosa, most patients with severe or complicated oesophagitis experience persistent heartburn, regurgitation or dysphagia. 9 Based on the results of a population-based study that found a positive association between severity and frequency of symptoms (P < 0.001) and between symptom frequency and number of physician visits (odds ratio, 6.2; 95% confidence interval, 3.6-10.7), one can conclude that seeking the assistance of a physician for symptom relief may be a good indicator that GERD symptoms are severe. 1 However, many patients may not judge their symptoms to be severe enough to warrant medical attention. A survey of patients experiencing heartburn at least once a week found that 42% believed their symptoms were not serious enough to seek medical help. 3 Recognizing supra-oesophageal symptoms Otolaryngeal symptoms of GERD, which include hoarseness, laryngitis, laryngospasm, cough, globus sensation, excessive throat mucus, chronic throat clearing and chronic sore throat, can present in the absence of classic reflux symptoms or endoscopic changes. As many as 50% of all patients who have symptoms of excessive salivation, hoarseness, sore throat or persistent cough attributable to acid reflux do not exhibit any typical reflux symptoms. 1 In one study of 225 consecutive patients with otolaryngeal disorders suspected of having GERD, 24-h pH monitoring showed that 62% of the patients had abnormal oesophageal acid exposure and 30% had reflux into the pharynx, even though 57% had no oesophageal symptoms. 10 Although these statistics may be at the high end of the range for patients with supra-oesophageal symptoms (the overall association is likely to be less than one-third of patients having documented reflux), physicians should consider GERD in patients presenting with a history of repetitive throat clearing, recurrent hoarseness (particularly in the morning) or cough-even in the absence of heartburn. 11, 12 Similarly, a large proportion of non-allergic asthma patients may have reflux without having heartburn or dyspepsia. GERD should be considered in patients with adult-onset asthma and in those whose asthma is refractory to customary asthma treatment. The exact contribution of reflux to the pathogenesis of asthma, or vice versa, has not been fully elucidated, but some studies demonstrate symptomatic improvement in response to empirical proton pump inhibitor treatment in asthmatic patients. 13, 14 In a study of asthmatic patients with nocturnal wheezing and chronic cough, but no reflux symptoms, 62% had abnormal 24-h oesophageal pH tests. No demographic variables were predictive of reflux in the asymptomatic patients, which underscores the importance of 24-h pH testing for a more accurate diagnosis. 15 The question of improved 24-h pH profiles in response to better asthma treatment is also now being studied.
Complaints of sleep disturbances may also serve as a warning sign in patients with GERD. Oesophageal and supra-oesophageal symptoms may cause loss of sleep, fatigue, snoring and breathlessness, which lead to reduced quality of life and work productivity. 5, 16 
Diagnostic methods
Symptom relief is an important goal of treatment, but many patients with heartburn have no abnormality seen at endoscopy, therefore empirical treatment has been advocated for transient or intermittent symptoms. 17, 18 Relief of symptoms with 1 week of therapy with omeprazole 20 mg b.d. is associated with a diagnostic sensitivity of 75% and specificity of 55% compared with endoscopy and ambulatory pH monitoring. 19 Compared with 24-h oesophageal pH testing, a therapeutic trial using omeprazole 40 mg once-daily yielded positive and negative predictive values of 68% and 63%, respectively. 20 In most cases where proton pump inhibitor therapy has been used as a diagnostic test for reflux as a cause of symptoms, a twice-daily omeprazole dosing regimen was employed. 21 In general, failure to improve after 2 weeks of proton pump inhibitor therapy warrants referral to a gastroenterologist for diagnostic evaluation. Although empirical treatment can be helpful in identifying GERD, a recent meta-analysis failed to support proton pump inhibitor therapy as a reliable diagnostic procedure. In that study, proton pump inhibitor therapy was found to correlate only weakly with more objective diagnostic measures such as ambulatory pH and endoscopy. 22 In addition, a response to empirical proton pump inhibitor therapy does not exclude or identify Barrett's oesophagus or GERD complications. Empirical proton pump inhibitor therapy may be appropriate for patients in whom the diagnosis of GERD appears straightforward, but should not be used in patients presenting with alarm symptoms suggesting the possibility of serious complications (Table 2) . 17 Those patients need to undergo upper endoscopy and be treated promptly. The duration of reflux has been directly associated with an increased risk of complications, therefore endoscopic screening should be considered in patients over age 50 who exhibit chronic GERD symptoms. No further surveillance is required in the absence of Barrett's oesophagus at the first endoscopy. 17 Endoscopy with biopsy is the only reliable method of diagnosing Barrett's oesophagus. 17, 23 Availability of ultra-thin flexible endoscopes facilitate endoscopic diagnosis and may offer a more cost-effective approach than conventional endoscopy. 24 GERD symptoms result from acidic gastric contents entering the oesophagus and not just from excessively low pH of the gastric contents in the absence of reflux. Thus, gastric pH monitoring is not of direct utility in the diagnosis of GERD. In contrast, ambulatory oesophageal pH monitoring enables evaluation of the frequency and duration of episodes during which the oesophagus is exposed to pH < 4. A dual oesophageal probe is sometimes used, which involves a second probe placed in the upper oesophagus allowing documentation of proximal reflux (Figure 1) . 25, 26 Although increased acid reflux into the proximal oesophagus can be demonstrated in many GERD patients with laryngeal symptoms, technical limitations remain and the association of such reflux and symptoms requires clarification. One such limitation is the lack of consensus for the location and placement of the proximal probe, which can have an impact on the results of the test. 27 In various studies, the proximal pH probes have been placed 20 cm above the lower oesophageal sphincter, just below the upper oesophageal sphincter, or in the hypopharynx. Normal values of acid exposure, for each position of the probe, remain to be established in adequate numbers of subjects. At present, these kinds of measurements are largely confined to a research setting and are of little use in ordinary practice. General consensus among otolaryngologists is that in order to diagnose supraesophageal reflux, a pH probe needs to be placed outside the confines of the oesophagus, in the hypopharynx. 28 In many instances, physicians use the response to empirical treatment with acid-suppressive therapy for deciding whether or not a symptom (i.e. hoarseness) is attributable to reflux, reserving pH monitoring mainly for refractory cases. Among patients who do not respond to an aggressive therapeutic trial of proton pump inhibitors, pH monitoring may be helpful in clarifying the existence or absence of GERD. Caution should be used in interpreting negative results of pH 17 monitoring because of the intermittent nature of reflux. A negative study should prompt a careful search for an alternative cause of symptoms.
MANAGEMENT OF REFLUX
The goals of therapy for GERD are symptom relief and prevention, healing and maintenance of healing, prevention of oesophagitis or prevention of recurrent oesophagitis, and reduction in the risk of developing long-term complications (e.g. strictures, oesophageal ulcers).
Lifestyle changes
Although few studies have assessed the benefits of lifestyle changes in reducing the symptoms and severity of GERD, patient education regarding such changes is considered an important adjunct to any pharmacological intervention (Table 3) . [29] [30] [31] [32] [33] Elevation of the head of the bed on 6-or 8-inch blocks (not the use of pillows) should be considered in the management of GERD patients with supine or nocturnal symptoms. 29 Additional recommendations include controlling weight, ingesting small meals, eating a low-fat diet, avoiding certain offending foods and allowing at least 3 h after ingesting a meal before reclining. Certain foods, including chocolate, mints, alcohol and coffee, among others, may exacerbate reflux.
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Pharmacological therapy
Several pharmacological agents are used in the treatment of GERD. Some agents can be taken as symptomatic therapy to relieve heartburn or other symptoms as they occur. Other medications are used long-term on a daily basis to heal the oesophageal mucosa and/or prevent the occurrence of symptoms. In those with night-time heartburn, one must carefully weigh Ôas-neededÕ or ÔprnÕ regimens against standard regimens that are aimed at preventing symptoms; because for night-time symptoms, as-needed regimens rely on the patient being awakened from sleep and taking corrective action. In the absence of full arousal, acid exposure and tissue injury continue. 34 For more information, see the paper by Orr et al. 35 in this supplement.
In order to optimize therapy, an understanding of the basic pharmacology of the agents available for the treatment of GERD is necessary. For example, the fact that histamine-2 receptor antagonists (H 2 RAs) reduce postprandial gastric acid secretion 36, 37 may lead the clinician to choose these agents in the management of patients with intermittent symptoms that occur only after meals. All proton pump inhibitors work in a similar manner, inhibiting only H + ,K + ATPase that is active. Moreover, maximal recruitment of proton pumps to the parietal cell apical surface takes several days to achieve, and maximal acid inhibition is not achieved until the third to fifth day of therapy (Figure 2 ). [38] [39] [40] All of the proton pump inhibitors are prodrugs absorbed in the small intestine. Four of the currently available agents (omeprazole, lansoprazole, pantoprazole and rabeprazole) are marketed as racemic mixtures that contain equal amounts of R and S enantiomers. The fifth, esomeprazole, contains only the S-isomer of omeprazole. 41 Only after the proton pump inhibitor is absorbed and directed into the acidic environment of the parietal cell does it become protonated and converted into the active moiety that binds to cysteine residues on the H + ,K + ATPase enzyme, thereby inhibiting acid secretion. 42 Insufficient data are available to conclude whether structural or pharmacokinetic differences among proton pump inhibitors translate into clinical superiority for any one proton pump inhibitor. However, the key concepts that should be kept in mind when using a proton pump inhibitor to treat night-time heartburn are outlined in Table 4 . 38, 40, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Several excellent review articles describe the pharmacological properties of antacids, H 2 RAs and proton pump inhibitors in considerably more detail.
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Comparative efficacy
Twenty-four hour ambulatory pH monitoring has been used to compare the effects of different proton pump inhibitors. The level of intra-oesophageal pH is a reasonable measure of success in treating GERD, but it is not a reliable surrogate for symptom relief. This was apparent in a study examining the effects of lansoprazole or pantoprazole on intra-oesophageal pH. All 45 Figure 2. Steps to the mechanism of action of proton pump inhibitors. patients with heartburn/acid regurgitation at baseline were reported as being symptom-free at the end of the study; however, oesophageal acid exposure remained abnormal in 44% of patients. 57 The number of studies assessing the efficacy of pharmacological therapy specifically for night-time GERD is limited, and comparisons between them are difficult due to variability among study designs and endpoints. Few studies have specifically addressed the relief of night-time GERD symptoms by proton pump inhibitors. Typically, these studies asked patients to rate the severity of their symptoms based on the duration, frequency and extent of interference with daily activities. The ratings and the symptoms addressed varied, with some studies addressing only the presence of heartburn, [58] [59] [60] whereas others included additional symptoms such as regurgitation, dysphagia and belching. [61] [62] [63] [64] In some studies, the effect of therapy on nighttime symptoms may be inferred from endpoints such as a 24-h symptom-free period. 57, 60 There are no studies assessing supra-oesophageal manifestations of GERD that occur in association with night-time reflux. The definition of what constitutes complete or sustained symptom relief varies from trial to trial. In one study comparing pantoprazole 20 mg and 40 mg daily with nizatidine 150 mg twice daily, patients were considered to have complete symptom resolution on the first day in which they reported no symptoms if they remained symptom-free for the remainder of the 8-week study period. 65 In contrast, other studies defined sustained resolution as 7 consecutive heartburn-free days, regardless of when this occurred. 58, 59 Table 5 summarizes characteristics of comparative studies that include data pertaining to the effect of proton pump inhibitors on night-time GERD symptoms. 58, 59, 63, 64, [66] [67] [68] [69] Overall, based on the available information, all the proton pump inhibitors are safe and have beneficial effects in patients with GERD. However, it cannot be REVIEW: DIAGNOSIS AND MANAGEMENT OF NIGHT-TIME REFLUX concluded that one agent is significantly better than another. Although it has been suggested that some proton pump inhibitors may have a faster initial onset than others, 70 there are no differences in long-term effectiveness. 71 Data are now emerging regarding the impact of proton pump inhibitor therapy on sleep disturbances in GERD patients that suggest significant benefits of treatment over no treatment, but evaluation of the clinical implications of these findings awaits full publication of trial results.
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TREATMENT STRATEGIES
Management of breakthrough symptoms
In an effort to reduce the costs of long-term care of GERD patients, various approaches to dosing have been used. For some patients who have mild and/or occasional symptoms, antacids and/or H 2 RAs may be used as needed for symptom relief.
Persistent night-time symptoms
For patients with more serious and/or more persistent symptoms, a traditional approach has been to start with lifestyle modifications and use progressively more intense antisecretory therapy. Alternatively, patients may be started on relatively high doses of antisecretory medication and gradually Ôstepped-downÕ to a less potent maintenance dose. Intermittent treatment programmes involving proton pump inhibitors have been used, in which treatment is initiated by the patient when symptoms occur. In such cases, the medication is administered as a short course of daily treatment, customarily of 2-4 weeks' duration. Treatment is then discontinued until symptoms return. Intermittent therapy may be particularly well suited to patients with uncomplicated GERD and may be effective in reducing costs. 75 Mathematical models have suggested that step-down therapy may be cost effective when compared with stepup treatment. 21 However, comparative evaluations of step-up vs. step-down vs. fixed-dose therapy have yielded inconclusive results regarding efficacy. In a community-based study, 593 heartburn patients were randomized to receive either ranitidine 150 mg b.d. or lansoprazole 30 mg once daily for 20 weeks (fixeddose); ranitidine 150 mg b.d. for 8 weeks followed by lansoprazole 30 mg once daily for 12 weeks (step-up); Fixed-dose proton pump inhibitor treatment provided more consistent heartburn relief than H 2 RA, step-up or step-down treatments after 20 weeks of follow-up. 60 In contrast, another study of 73 patients treated in a primary care setting assessing step-down therapy found that most patients who were Ôstepped-downÕ from proton pump inhibitor treatment to no therapy or high-dose H 2 RA therapy with or without prokinetic drug added after initial symptom relief were maintained successfully at 1-year follow-up. 76 Patients were included in this study if they had been prescribed proton pump inhibitors for more than 8 weeks. 76 In this study the response to step-down from proton pump inhibitors differed with the primary symptom (heartburn as the dominant symptom was associated with a need for continued proton pump inhibitor therapy 76 ) and with the duration of proton pump inhibitor treatment before the study. 77 Based on these data, the benefit of fixeddose treatment with proton pump inhibitor therapy needs to be evaluated on an individual basis until optimal treatment strategies for specific patient groups are defined. 78 When proton pump inhibitors are used to control symptoms, using the lowest effective maintenance dose as early as possible in the treatment programme is recommended. 79 In patients with nighttime reflux, symptoms may be more subtle and varied than those associated with daytime reflux and close attention to their response to the medication is required.
Treatment options for symptomatic GERD
Over-the-counter medications. As noted earlier, changes in lifestyle that may potentially improve GERD symptoms are considered to be important in all patients. Over-the-counter medications including antacids, H 2 RAs or a combination of the two can provide prompt, relatively transient relief of symptoms such as heartburn or regurgitation, but their short duration of action limits their daily use in many cases. Omeprazole is now available over the counter. Its maximum effect is not achieved for 3-5 days into therapy, similar to other proton pump inhibitors, thus it is not considered an effective choice for immediate relief. This carries a significant risk of improper dosing by the public. Pharmacokinetic principles dictate that proton pump inhibitors should be taken approximately 30 min before a meal (before breakfast for once-daily dosing)
and not be taken with a variety of other drugs, including H 2 RAs (Table 4) . 38, 40, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] The importance of proper dosing should not be underestimated. Despite widespread use of proton pump inhibitors for more than 15 years and their immense popularity, a lack of understanding still exists with regard to the proper use of these drugs-even among physicians. A recent survey found that only 28% of primary care physicians, who comprise nearly 80% of proton pump inhibitor prescribers, appropriately directed their patients to take their proton pump inhibitor before breakfast. 80 Furthermore, although gastroenterologists recommended that their patients take proton pump inhibitors before breakfast more often than their primary care colleagues, 11% of those specialists responded that the time of administration did not matter. 80 Effective use of overthe-counter proton pump inhibitors would seem to require that patients do better than physicians seem to do in understanding the importance of timing the ingestion of the drug in relation to meals. The use of over-the-counter proton pump inhibitors raises several additional concerns, most notably the delay in diagnosis of more serious conditions. Beyond this, results from a survey commissioned by the American Pharmacy Association reveal that patients often do not read over-the-counter product labels and may not be aware of potential risks associated with the use of nonprescription products. 81 This survey arouses concern because inappropriate treatment of reflux can lead to serious consequences. Proton pump inhibitors are metabolized via cytochrome P450 isoenzymes 2C19 and 3A4 (CYP2C19 and CYP3A4, respectively), therefore a small potential exists for drug interactions. The genetically determined rate at which proton pump inhibitors are metabolized by CYP2C19 has implications for the duration of acid suppression. For example, in pharmacodynamic studies, the area under the curve for omeprazole has been shown to be greater in poor metabolizers than in extensive metabolizers, 82 and the former may be at increased risk for adverse effects. 83, 84 Up to 22% of Japanese people may fall into this Ôslow metabolizerÕ category owing to a genetic mutation in CYP2C19. 85 Prescription medications. For patients with persistent night-time reflux symptoms who do not respond to lifestyle modification and over-the-counter medications, prescription medication is required. Patient-initiated therapy using over-the-counter or intermittent treat-ment is not sufficient or appropriate for these patients, because without medical evaluation and supervised treatment, erosive oesophagitis may occur or progress in a small, but significant, percentage of cases.
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H 2 RAs provide symptom relief but are not as effective as proton pump inhibitors in achieving mucosal healing. A meta-analysis of studies enrolling patients with GERD grades II-IV found that healing mild-to-moderate erosive oesophagitis requires 8-12 weeks of treatment with H 2 RAs, whereas time to healing is 4-6 weeks with proton pump inhibitor treatment. Moreover, the rate of healing at 2 weeks associated with proton pump inhibitor use in this study was superior to that with H 2 RAs after 12 weeks (Figure 3) . 50 Lower oesophageal sphincter mechanism incompetence, poor oesophageal acid clearance, decreased salivary secretion of bicarbonate, and delayed gastric emptying can be important in producing or exacerbating night-time reflux symptoms in patients with GERD. Promotility therapy has been found to be beneficial in treating GERD. [87] [88] [89] The dopamine antagonist metoclopramide may provide symptom relief by improving gastric motility. However, this agent is not effective in inducing oesophageal mucosal healing and its longterm use is seriously limited by the occurrence of serious side-effects. The efficacy of cisapride, which stimulates acetylcholine release from the mesenteric plexus indirectly affecting gut motility, is similar to H 2 RAs in achieving symptom relief and mucosal healing. However, cisapride has been associated with rare, but sometimes fatal, cardiac arrhythmias. As a result, the manufacturer removed cisapride from the US market in July 2000, but continues to make it available for patients meeting the specific eligibility requirements of a limited access protocol. 90 There is currently no prokinetic drug with a recognized indication in GERD or gastroparesis available on the US market.
Treatment options for healing endoscopically proven GERD Healing therapy. Traditionally, daily treatment with standard doses of proton pump inhibitors for 8 weeks has been used for initial management of endoscopically proven GERD. Although not approved by the Food and Drug Administration, twice-daily dosing may provide superior inhibition of acid secretion in patients with severe or resistant symptoms or with supra-oesophageal manifestations of reflux, which have been reported to be more common in those with night-time reflux. 5 Gastric acid suppression has been found to be superior in response to omeprazole 20 mg b.d. compared with either omeprazole 20 mg or 40 mg once daily. 91 However, although gastric acid suppression may be more effective with twice-daily dosing, mucosal healing over a period of weeks has not been shown to be improved by twice-daily dosing: rabeprazole 20 mg once daily and 10 mg twice daily and omeprazole 20 mg once daily were shown to have similar efficacy in inducing oesophageal mucosal healing as determined by endoscopy. 92 Maintenance therapy. After 6 weeks of proton pump inhibitor therapy in patients with erosive oesophagitis, oesophageal mucosa has been reported to be healed in more than 80% of patients. 50 However, relief of some supra-oesophageal symptoms, often associated with substantial night-time reflux, may require a longer duration (6 months or more) of treatment.
93, 94
The proton pump inhibitor dose required for maintenance of healing and symptom relief seems to be similar to the healing dose. In a study of patients successfully treated initially with healing doses of esomeprazole (40 mg or 20 mg) or omeprazole (20 mg), fewer than 60% of those receiving a smaller subsequent maintenance dose of esomeprazole 10 mg were still in remission at the end of the study. 95 Similar results were found Although stepping-down to low-dose therapy may seem initially to be less costly, the ramifications of relapse for the patient and the utilization of medical resources must be considered. To that end, evidencebased treatment protocols looking at total costs and patient outcomes should be used by third-party payers to determine formulary approvals and first-tier co-payment level. Proton pump inhibitor therapy has been used extensively in patients with night-time reflux. Reduction of night-time intragastric pH to less than 4 for more than 1 h has been reported in both normal volunteers receiving twice-daily proton pump inhibitor therapy and in as many as 73% of patients with GERD. 96 This night-time decrease in gastric pH of more than 1 h in duration is referred to as nocturnal acid breakthrough. The relevance of nocturnal acid breakthrough to oesophageal disease or GERD symptoms has not been established. 97, 98 A retrospective review of patients receiving ranitidine, famotidine or nizatidine added to omeprazole b.d. or lansoprazole b.d. at bedtime showed a reduced incidence of nocturnal acid breakthrough and reduced oesophageal exposure to acid during nocturnal acid breakthrough, but these results have been neither confirmed nor shown to have an impact on clinical outcomes. 99 A crossover study found that the addition of ranitidine 300 mg to treatment with omeprazole 20 mg twice daily did not enhance proton pump inhibitor efficacy in nocturnal gastric pH control. 97 Nocturnal acid breakthrough was found to persist in 59-91% of patients despite elimination of oesophageal acid reflux and symptoms in 90% and 100% of patients, respectively.
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Use of defined short-term or intermittent proton pump inhibitor therapy. As noted earlier, defined durations of intermittent courses of therapy, used when required, have been proposed as a treatment option for some patients with uncomplicated GERD. These treatment regimens involve the use of short, defined, but limited sequences of daily proton pump inhibitor therapy. A multicentre, randomized study found that omeprazole was superior to ranitidine when administered as intermittent courses of 2-4 weeks' duration in patients with uncomplicated GERD. 100 This study showed that three 2-week courses per year controlled GERD symptoms in most patients. However, the impact of shortcourse intermittent therapy on disease progression has not been evaluated.
CONCLUSIONS
Symptoms from night-time reflux range from mild to severe. They may be similar to those of daytime reflux and exacerbated by recumbency, or may differ in their presentation, with symptoms such as nocturnal cough, nocturnal restlessness, night-time awakenings, or fatigue. Supra-oesophageal symptoms including pulmonary and otolaryngologic complaints, common in patients with night-time symptoms, may be easily overlooked. Endoscopy is appropriate in some cases to evaluate the presence, extent or severity of oesophagitis, but endoscopic findings are normal in many patients, even when symptoms are severe. In general, 24-h oesophageal pH monitoring is of value in confirming the presence of reflux in patients with suggestive symptoms. Endoscopy may be helpful in evaluating patients who have failed empirical therapy or in screening for Barrett's oesophagus. In all, 24-h oesophageal pH monitoring is of greatest value in establishing the presence or absence of reflux and the response to proton pump inhibitor therapy. Mild-to-moderate reflux with occasional or intermittent symptoms can often be managed with a combination of lifestyle changes and as-needed use of H 2 RAs and/or antacids. Use of over-the-counter proton pump inhibitor treatment (e.g. omeprazole) is readily available but requires careful patient counselling to ensure that the drug is being used appropriately and dosing is adequate. More severe, persistent and complicated disease requires continued treatment with a prescription proton pump inhibitor.
Studies indicate that night-time reflux is associated with a longer duration of oesophageal exposure to gastric acid, leading to more severe oesophageal and supra-oesophageal injury, therefore increased awareness on the part of both physicians and patients and more aggressive treatment may be needed. Proton pump inhibitors are the treatment of choice for healing GERD and managing patients with severe night-time reflux. The dosing regimen selected for maintenance therapy should be dictated by assessment of the patient's requirements, and rarely differs from the dose required for the initial response in that same patient.
